Market accessOfficial

Teva Denmark permanently withdraws Orlistat 120 mg capsules from Danish market

🇩🇰 DKMA · Wed 04 Nov 2026

The Danish Medicines Agency has posted a supply notice saying Teva Denmark A/S has stopped marketing Orlistat "Teva" 120 mg hard capsules for commercial reasons.

The Danish Medicines Agency (DKMA) has published a supply notice, dated 4 November 2026, confirming that marketing of Orlistat "Teva" 120 mg hard capsules by Teva Denmark A/S has ended.

The notice gives the active substance as orlistat (ATC code A08AB01). The expected period is stated as from the end of October 2026, and the reason is given as commercial. Under additional information, DKMA describes the move as a permanent market discontinuation.

This differs from a temporary shortage: the notice does not point to a planned return of the product. The agency does not list alternative products or say how patient access may be affected. It directs questions about the current status to the company.

The notice appears in DKMA's section on medicines supply announcements.

What it means for your team

  • Supply-chain and commercial teams should treat this as a permanent withdrawal of the Teva 120 mg presentation in Denmark, not a temporary interruption.
  • Market-access and pharmacy-facing teams may wish to check which other orlistat 120 mg products remain available in Denmark, as the notice names none.
  • Regulatory and QA staff should update product and portfolio trackers and contact Teva Denmark for the current status, as DKMA advises.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Market access All →